Novo Nordisk A/S
CPSE-NOVO B
Company Overview
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Name
Novo Nordisk A/S
CEO
Mr. Lars Fruergaard Jorgensen
Website
www.novonordisk.com
Sector
Pharmaceuticals
Year Founded
1923
Profile
Market Cap
DKK 4,071.85B
EV
DKK 4,066.25B
Shares Out
4,433.15M
Revenue
DKK 258B
Employees
69,260
Margins
Gross
84.53%
EBITDA
49.05%
Operating
45.96%
Pre-Tax
43.77%
Net
34.84%
FCF
31.46%
Returns (5Yr Avg)
ROA
29.76%
ROTA
140.26%
ROE
78.16%
ROCE
78.38%
ROIC
32.2%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
DKK 967.54
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
DKK 62.65B
Net Debt
-DKK 5,594M
Debt/Equity
0.51
EBIT/Interest
218.77
Growth (CAGR)
Rev 3Yr
25.7%
Rev 5Yr
17.17%
Rev 10Yr
11.85%
Dil EPS 3Yr
28.06%
Dil EPS 5Yr
20.75%
Dil EPS 10Yr
15.21%
Rev Fwd 2Yr
22.58%
EBITDA Fwd 2Yr
25.51%
EPS Fwd 2Yr
24.61%
EPS LT Growth Est
21.81%
Dividends
Yield
—
Payout
49.15%
DPS
DKK 9.9
DPS Growth 3Yr
28.42%
DPS Growth 5Yr
19.43%
DPS Growth 10Yr
15.97%
DPS Growth Fwd 2Yr
26.45%